mesalamine and ajm300

mesalamine has been researched along with ajm300 in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Hibi, T; Hirai, F; Ishida, T; Ishiguro, Y; Kajioka, T; Kanke, K; Kishida, S; Kobayashi, K; Matsuoka, K; Miura, Y; Mizusawa, H; Nakajima, K; Ohmori, T; Ohta, A; Watanabe, K; Watanabe, M1

Trials

1 trial(s) available for mesalamine and ajm300

ArticleYear
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
    The lancet. Gastroenterology & hepatology, 2022, Volume: 7, Issue:7

    Topics: Colitis, Ulcerative; Humans; Induction Chemotherapy; Integrin alpha4; Mesalamine; Nasopharyngitis; Phenylalanine; Quinazolinones; Treatment Outcome

2022